UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1042-13
Program Prior Authorization/Notification
Medication Hycamtin® (topotecan hydrochloride)
Date Approved 1/12/2010, 9/2010, 12/2010, 7/2011, 8/2012, 2/2014, 2/2015, 2/2016,
12/2016, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021, 11/2022,
11/2023, 11/2023
Date Revised 2/1/2025
1. Background:
Hycamtin (topotecan hydrochloride) is a topoisomerase inhibitor indicated for the treatment of
patients with relapsed small cell lung cancer. The National Cancer Comprehensive Network
(NCCN) also recommends Hycamtin may be considered as single-agent treatment (useful in
certain circumstances) for M1 disseminated disease with or without surgery and/or radiation
therapy if anti-PD-L1 or anti-PD-1 therapy is contraindicated or disease has progressed on anti-
PD-L1 or anti-PD-1 therapy.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of 19
years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or under
some circumstances. Some states also mandate usage of other Compendium references. Where such
mandates apply, they supersede language in the benefit document or in the notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Hycamtin will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Small cell lung cancer (SCLC)
1. Initial Authorization
a. Hycamtin will be approved based on all of the following criteria:
(1) Diagnosis of small cell lung cancer (SCLC)
-AND-
(2) Patient has experienced a relapse of disease after initial first-line chemotherapy
© 2024 UnitedHealthcare Services, Inc.
1
(e.g., cisplatin with etoposide)
Authorization will be issued for 12 months.
2. Reauthorization
a. Hycamtin will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Hycamtin
therapy
Authorization will be issued for 12 months.
C. Merkel cell carcinoma
1. Initial Authorization
a. Hycamtin will be approved based on all of the following criteria:
(1) Diagnosis of Merkel cell carcinoma
-AND-
(2) Disease is M1 disseminated
-AND-
(3) Patient has a contraindication to or disease has progressed on anti-PD-L1 or
anti-PD-1 therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Hycamtin will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Hycamtin
therapy
Authorization will be issued for 12 months.
D. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
2
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Hycamtin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;
September 2018.
The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed on
October 11, 2024.
Program Prior Authorization/Notification - Hycamtin (topotecan hydrochloride)
Change Control
2/2014 Annual review. No change to coverage criteria.
2/2015 Annual review. Added additional criteria to SCLC indication. Updated
references.
2/2016 Annual review. Changed all authorization to 12 months. Updated
references.
12/2016 Annual review. Updated references.
11/2017 Annual review. Updated references.
11/2018 Annual review. Added coverage for Merkel cell carcinoma based on
NCCN guidelines. Updated background and references.
11/2019 Annual review. Added NCCN recommended regimens criteria.
Updated references.
11/2020 Annual review. Updated background to reflect package insert.
Updated SCLC criteria to reflect package insert. Updated references.
11/2021 Annual review. Added clinical criteria for uterine neoplasms per
NCCN recommendations. Updated reference.
11/2022 Annual review. Removed criteria for uterine neoplasms since dosage
form for treatment is IV. Added state mandate footnote. Updated
reference.
11/2023 Annual review. Updated Merkel cell carcinoma criteria based on
current NCCN recommendations. Updated background and reference.
11/2024 Annual review with no changes to coverage criteria.
© 2024 UnitedHealthcare Services, Inc.
3